Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Production and purification of Streptococcus pneumoniae hemolysin (pneumolysin).

Literature DB >> 3818918

Production and purification of Streptococcus pneumoniae hemolysin (pneumolysin).

Abstract

Pneumolysin was found to be produced by 112 of 113 clinical isolates of Streptococcus pneumoniae and to be an intracellular hemolysin. A 10-liter-scale fermentor production and purification procedure was developed for this hemolysin. The culture was concentrated by filtration 10 times before centrifugation. The cellular content was purified by ion-exchange chromatography, covalent thiopropyl gel chromatography, and gel filtration. One batch operation resulted in 6 mg of highly purified pneumolysin, with a yield of 66% and a specific activity of 1,400,000 hemolytic units per mg. The pneumolysin had a molecular weight of 53,000 and an isoelectric point of 5.2. The purification method developed will be of value in future studies on this hemolysin.

Mesh：

Substances：

Year: 1987 PMID： 3818918 PMCID： PMC265871 DOI： 10.1128/jcm.25.2.222-225.1987

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

14 in total

1. Pneumococcal Hemolysin: The Preparation of Concentrates, and Their Action on Red Cells.

Authors: B Cohen; S P Halbert; M E Perkins
Journal: J Bacteriol Date: 1942-05 Impact factor: 3.490

2. Ocular toxin of the pneumococcus.

Authors: M K Johnson; J H Allen
Journal: Am J Ophthalmol Date: 1971-07-30 Impact factor: 5.258

3. Activation of human complement by the pneumococcal toxin pneumolysin.

Authors: J C Paton; B Rowan-Kelly; A Ferrante
Journal: Infect Immun Date: 1984-03 Impact factor: 3.441

4. Isolation and characterization of pneumolysin-negative mutants of Streptococcus pneumoniae.

Authors: M K Johnson; D Hamon; G K Drew
Journal: Infect Immun Date: 1982-08 Impact factor: 3.441

5. Effects of pneumolysin on human polymorphonuclear leukocytes and platelets.

Authors: M K Johnson; D Boese-Marrazzo; W A Pierce
Journal: Infect Immun Date: 1981-10 Impact factor: 3.441

6. Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin.

Authors: A Ferrante; B Rowan-Kelly; J C Paton
Journal: Infect Immun Date: 1984-11 Impact factor: 3.441

7. Properties of purified pneumococcal hemolysin.

Authors: M K Johnson
Journal: Infect Immun Date: 1972-11 Impact factor: 3.441

8. Diagnosis of pneumococcal pneumonia by enzyme-linked immunosorbent assay of antibodies to pneumococcal hemolysin (pneumolysin).

Authors: M Kalin; K Kanclerski; M Granström; R Möllby
Journal: J Clin Microbiol Date: 1987-02 Impact factor: 5.948

9. Pneumococcal beta hemolysin produced under the effect of antibiotics.

Authors: V Lorian; A Waluschka; B Popoola
Journal: Appl Microbiol Date: 1973-02

10. Antibiotic sensitivity of Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes and Branhamella catarrhalis isolated from upper respiratory tract infections in Sweden.

Authors: I Kallings; S Bengtsson; P Christensen; S E Holm; L Lind; M Kalin
Journal: Scand J Infect Dis Suppl Date: 1983

28 in total

1. Rapid and reliable identification of Streptococcus pneumoniae isolates by pneumolysin-mediated agglutination.

Authors: M D Cima-Cabal; F Vázquez; J R de los Toyos; F J Méndez
Journal: J Clin Microbiol Date: 1999-06 Impact factor: 5.948

2. CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection.

Authors: Aras Kadioglu; William Coward; M Joseph Colston; Colin R A Hewitt; Peter W Andrew
Journal: Infect Immun Date: 2004-05 Impact factor: 3.441

Review 3. Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins.

Authors: Rodney K Tweten
Journal: Infect Immun Date: 2005-10 Impact factor: 3.441

4. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines.

Authors: Lea-Ann S Kirkham; Alison R Kerr; Gill R Douce; Gavin K Paterson; Deborah A Dilts; Dai-Fang Liu; Tim J Mitchell
Journal: Infect Immun Date: 2006-01 Impact factor: 3.441

5. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.

Authors: Philippe Denoël; Mario T Philipp; Lara Doyle; Dale Martin; Georges Carletti; Jan T Poolman
Journal: Vaccine Date: 2011-05-30 Impact factor: 3.641

6. Differences in virulence for mice among Streptococcus pneumoniae strains of capsular types 2, 3, 4, 5, and 6 are not attributable to differences in pneumolysin production.

Authors: K A Benton; J C Paton; D E Briles
Journal: Infect Immun Date: 1997-04 Impact factor: 3.441

7. Effect of Streptococcus pneumoniae on human respiratory epithelium in vitro.

Authors: C Steinfort; R Wilson; T Mitchell; C Feldman; A Rutman; H Todd; D Sykes; J Walker; K Saunders; P W Andrew
Journal: Infect Immun Date: 1989-07 Impact factor: 3.441

8. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae.

Authors: J E Alexander; R A Lock; C C Peeters; J T Poolman; P W Andrew; T J Mitchell; D Hansman; J C Paton
Journal: Infect Immun Date: 1994-12 Impact factor: 3.441

9. Differences in clinical manifestation of Streptococcus pneumoniae infection are not correlated with in vitro production and release of the virulence factors pneumolysin and lipoteichoic and teichoic acids.

Authors: Annette Spreer; Astrid Lis; Joachim Gerber; Ralf René Reinert; Helmut Eiffert; Roland Nau
Journal: J Clin Microbiol Date: 2004-07 Impact factor: 5.948

10. Role of Toll-like receptors 2 and 4 in pulmonary inflammation and injury induced by pneumolysin in mice.

Authors: Mark C Dessing; Robert A Hirst; Alex F de Vos; Tom van der Poll
Journal: PLoS One Date: 2009-11-24 Impact factor: 3.240